New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2014
07:40 EDTHTWR, THORHeartWare remains well positioned in LVAD market, says Leerink
Leerink attributes HeartWare's (HTWR) disappointing Q4 sales to company-specific issues and broader market weakness. The firm expects competitor Thoratec (THOR) to trade lower on the potential for LVAD market weakness, but keeps Outperform ratings on companies. Leerink still views Thoratec as well positioned in the LVAD market and sees potential catalysts in 2014.
News For HTWR;THOR From The Last 14 Days
Check below for free stories on HTWR;THOR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
07:21 EDTHTWR, THORHeart Failure Society of America to hold annual meeting
Subscribe for More Information
September 9, 2014
16:46 EDTTHORThoratec announces start of Heartmate III U.S. clinical trial
Subscribe for More Information
September 4, 2014
10:01 EDTTHORThoratec management to meet with Oppenheimer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use